Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts.

Braun Stacey Associates cut its stake in Regeneron Pharmaceuticals by 4.5% during the first quarter, lowering its holdings to ...

Genetic testing company 23andMe can proceed with a $305 million sale to the company’s co-founder Anne Wojcicki after a U.S.

This was the stock's second consecutive day of losses.

Vontobel Holding Ltd. increased its stake in Regeneron Pharmaceuticals by 13.6% in the first quarter, signaling bullish ...

Apogee Therapeutics Inc. plans to enter a crowded atopic dermatitis market with established drugs, such as Dupixent (dupilumab, Regeneron Pharmaceuticals Inc. and Sanofi SA) and Ebglyss ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Regeneron Pharmaceuticals, Inc.

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- The anti-inflammatory drugs market size has grown rapidly in recent years. From $136.86 billion in 2024, it is predicted to ...

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory ...

Stay Informed On Tariff Changes, Macroeconomic Trends, And More.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, July 3, 2025 /EINPresswire.com/ -- What Does The Growth ...